Zacks Research upgraded shares of Klabin (OTCMKTS:KLBAY – Free Report) from a strong sell rating to a hold rating in a research report released on Thursday morning,Zacks reports.
Klabin Price Performance
KLBAY stock opened at $7.54 on Thursday. The stock’s 50 day moving average price is $6.98 and its 200 day moving average price is $7.12. The firm has a market cap of $23.53 billion, a P/E ratio of 44.64, a PEG ratio of 2.01 and a beta of 0.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 1.37 and a current ratio of 1.78. Klabin has a 1 year low of $6.34 and a 1 year high of $10.23.
Klabin (OTCMKTS:KLBAY – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The basic materials company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Klabin had a return on equity of 1.79% and a net margin of 1.26%.The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. On average, sell-side analysts expect that Klabin will post 0.25 earnings per share for the current fiscal year.
Klabin Company Profile
Klabin SA is a Brazilian integrated paper and pulp company that develops, manufactures and sells a range of forest products and packaging solutions. Founded by the Klabin family in 1899 and headquartered in São Paulo, the company’s activities span forestry management, pulp and paper manufacturing, containerboard and corrugated packaging production, and recycling operations. Klabin supplies both industrial and consumer-oriented paper and packaging products, including kraftliner, corrugating medium, cartonboard and specialty papers used across multiple end markets.
As an integrated forest products company, Klabin manages planted timberlands and brings raw material through its own supply chain into pulping and papermaking facilities.
Read More
- Five stocks we like better than Klabin
- Lululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story
- MarketBeat Week in Review – 08/31 – 09/04
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
Receive News & Ratings for Klabin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Klabin and related companies with MarketBeat.com's FREE daily email newsletter.
